CANCER CLINICAL TRIALS

Amyloidosis Melanoma

Bladder Myelodysplastic Syndrome

Blood & Bone Myeloma

Marrow

<u>Brain</u> <u>Ovarian</u>

<u>Breast</u> <u>Pancreas</u>

<u>Cervical</u> <u>Prostate</u>

<u>Colorectal</u> Rare Tumors

Endometrial Rectal

Head & Neck Stomach

<u>Kidney</u> <u>Testicular</u>

Leukemia Uterine

<u>Lung</u> <u>Vulva – Vaginal</u>

<u>Lymphoma</u> <u>Multiple</u>

Please Note: Not all clinical trials are available at all care sites.

For more Information, please contact CancerCall:

(614) 566-4321 or 1 (800) 752-9119

AMYLOIDOSIS				
Type of Trial	Location	Trial Title	For more Information	
Immunotherapy	Bing	A Study of Daraumumab- Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis (AQUARIUS)	<u>Click Here</u>	
		Additional trials available under the "Multiple" section		

BLADDER

No BLADDER specific trials. Additional trials may be available under the "Multiple" section

BLOOD & BONE MARRROW				
Type of Trial	Location	Trial Title	For more Information	
Registry	Bing	CIBMTR Research Database (CIBMTR Research Data Base Protocol)		
Registry	Riverside	(FY24-34)		
Additional trials available under the "Multiple" section				

BRAIN

No BRAIN specific trials. Additional trials may be available under the "Multiple" section

BREAST			
Type of Trial	Location	Trial Title	For more Information
Biomarker	Bing Delaware Doctors Dublin Grant Mansfield Marion Riverside	CCTG MA.39_Tailor RT	
Radiation Therapy	Bing COHA Delaware Doctors Dublin Grady Grant Mansfield Marion	S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer (S1703)	<u>Click here</u>
Radiation Therapy	Delaware Doctors Dublin Grant Mansfield Marion Riverside	Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (Ascen_05)	<u>Click here</u>
	Addi	tional trials may be available under the "Multiple" section	

CERVICAL

No CERVICAL specific trials Additional trials may be available under the "Multiple" section

COLORECTAL					
Type of Trial	Location	Trial Title	For more Information		
Biomarker	Doctors Delaware Dublin Grant Mansfield Marion Riverside	Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays (TIME_Gemini CRC)	<u>Click here</u>		
		Additional trials may be available under the "Multiple" section			

ENDOME"	ENDOMETRIAL				
Type of Trial	Location	Trial Title	For more Information		
Registry	Bing Doctor's Dublin Grant Mansfield Marion O'Bleness Riverside Westerville	(ECMT2 Consortium Registry)			
Chemotherapy	Bing	Study of Navtemadlin as Maintenance Therapy in TP53WT Advance or Recurrent Endometrial Cancer (GOG-3089)	<u>Click here</u>		
	Add	itional trials may be available under the "Multiple" section			

HEAD & NECK

No HEAD & NECK specific trials. Additional trials may be available under the "Multiple" section

KIDNEY

No KIDNEY specific trials. Additional trials may be available under the "Multiple" section

LEUKEMIA

No LEUKEMIA specific trials. Additional trials may be available under the "Multiple" section

LUNG			
Type of Trial	Location	Trial Title	For more Information
Biomarker	Delaware Doctors Dublin Dublin Grant Mansfield Marion Riverside	TEMPUS GEMINI NSCLC STUDY: A Longitudinal Multi-Omic Biomaker Profiling Study of Patients With Non-Small Cell Lung Cancer (NSCLC) (TIME_Gemini NSCLC)	Click here
	Ado	litional trials may be available under the "Multiple" section	

LYMPHOMA					
Type of Trial	Location	Trial Title	For more Information		
Observational, Real-World Data	Bing	Observational Study of Patients With Relapsed or Refractory DLBCL Starting Second-or Third-line Therapy (realMIND) (MOR208C414_realMIND)	Click here		
		Additional trials may be available under the "Multiple" section			

MELANOMA					
Type of Trial	Location	Trial Title	For more Information		
Observational	Doctors Dublin Grant Riverside	DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)	<u>Click here</u>		
	Ado	ditional trials may be available under the "Multiple" section			

Type of Trial	Location	Trial Title	For more Information
Immunotherapy	Bing	Elranatamab Expanded Access protocol in Adults With Relapsed/Refractory Multiple Myeloma (MAGNETISMM17)	Click here
Registry	Delaware Doctors Dublin Cancer Center Dublin Grant Mansfield Marion Riverside	Buckeye Surveillance, Contact, and Research for MGUS, Myeloma, and Amyloidosis (OSU Buckeye Surveillance)	<u>Click here</u>
Immunotherapy	Bing	A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment (MonumenTAL-3)	<u>Click here</u>
Immunotherapy	Bing Delaware Doctors Dublin Cancer Center Dublin Grant Mansfield Marion O'Bleness	A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)(Halo)	<u>Click here</u>
Immunotherapy	Bing COHA Grady Marion Delaware Doctors Dublin Grant Mansfield Riverside	S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC) (S1803_DRAMMATIC)	Click here
Chemotherapy	Bing COHA Delaware Doctors Dublin Grant Mansfield Marion	Testing the Use of Combination Therapy in Adults Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trail (EAA181_EQUATE)	Click here

MYELOPDYSPLASTIC SYNDROME

No MYELOPDYSPLASTIC SYNDROME specific trials. Additional trials may be available under the "Multiple" section

OVARIAN

No OVARIAN specific trials. Additional trials may be available under the "Multiple" section

PANCREAS

No PANCREAS specific trials. Additional trials may be available under the "Multiple" section

PROSTATE

No PROSTATE specific trials. Additional trials may be available under the "Multiple" section

RARE TUMORS

No RARE TUMORS specific trials. Additional trials may be available under the "Multiple" section

RECTAL

No RECTAL specific trials. Additional trials may be available under the "Multiple" section

STOMACH

No STOMACH specific trials. Additional trials may be available under the "Multiple" section

TESTICULAR

No TESTICULAR specific trials. Additional trials may be available under the "Multiple" section

UTERINE

No UTERINE specific trials. Additional trials may be available under the "Multiple" section

VULVA-VAGINAL

No VULVA-VAGINAL specific trials. Additional trials may be available under the "Multiple" section

MULTIPLE

(Bladder, Blood & Bone Marrow, Brain, Breast, Cervical, Colorectal, Head & Neck, Kidney, Lung, Lymphoma, Melanoma, Myeloma, Ovarian, Pancreas, Prostate, Rectal, Testicular, Stomach, Uterine, Vulva – Vaginal)

Type of Trial	Location	Trial Title	For more Information
Targeted Therapy	Riverside	Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors (PAVO)	Click here
Targeted Therapy	Riverside	APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)	Click here
Health Outcomes	Delaware Doctors Grant Marion O'Bleness Riverside	Tempus Priority Study: A Pan-tumor Observational Study (TIME PRIORITY)	<u>Click here</u>
Chemotherapy	Bing	A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing CC-92480 (BMS-986348), Carfilzomib, and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (BMS CA057-008)	<u>Click here</u>
Chemotherapy	Bing	Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma (MAGNETISMM17) (C1071017 EAP)	<u>Click here</u>
Chemotherapy	Bing	Study with Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (MagnetisMM-7)	<u>Click here</u>
Chemotherapy	Bing	Open- Label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRM) EXCALIBER-RRMM) (CC-220-MM-002)	Click here